Legacy BioDesign Home

Recent News and Events

Legacy has conducted numerous formulation studies on peptides. Recently, we published some work we performed along with Dr. Gene Merutka, describing the stability of the bioactive peptide, teriparatide, after lyophilization and reconstitution.

“Stability of Lyophilized Teriparatide, PTH(1-34) After Reconstitution”, Gene Merutka, Brian M. Murphy, Glenn A. Wilson, James E. Matsuura, Charles S. Henry, and Mark Cornell Manning, Eur. J. Pharm. Biopharm. 2016, 99: 84-93.


All three companies in our strategic network (Legacy, WCB, and GLB) are focused on developing the best practices for evaluating aggregates and subvisible particles. Recently, we published a review of orthogonal methods to size exclusion chromatography (SEC):

“Review of Orthogonal Methods to Size Exclusion Chromatography (SEC) for Quantitation and Characterization of Protein Aggregates”, Ryan R. Manning, Ryan E. Holcomb, Glenn A. Wilson, Charles S. Henry, and Mark Cornell Manning, BioPharm Intl. 2014, 27(11): 32+.

Ryan Manning from GLB presented at the International Conference on Field-Flow Fractionation, Dresden, Germany, May 2016. His talk is entitled “Use of AF4 to Study Peptide Aggregation” by Ryan R. Manning, Robert W. Payne, Brian M. Murphy, Ryan E. Holcomb, Derrick S. Katayama, Glenn A. Wilson, and Mark Cornell Manning at the International Conference on Field-Flow Fractionation, Dresden, Germany, May 2016.

In addition, Legacy, GLB, and WCB presented a poster at the same meeting:
“Use of AF4 to Study the Conformation and Stability of Interferon-tau”, Ryan R. Manning, Ryan E. Holcomb, Auria Tellechea, Ryan J. Krammes, Nathan S. Krammes, Glenn A. Wilson, and Mark Cornell Manning, International Conference on Field-Flow Fractionation, Dresden, Germany, May 2016.


Dr. Derrick Katayama joined Legacy in July of 2015 as Principal Scientist. Previously Dr. Katayama held positions at Amylin, MedImmune, and Boehringer Ingelheim. We are delighted to have Derrick join us, bringing the total number of laboratory scientists at Legacy to four.

Dr. Ryan Holcomb was promoted to Senior Scientist, effective January 1, 2015.

According to ResearchGate, Dr. Manning had 1840 reads of his publications in 2015 and his work was cited 316 times in 2015 alone (over 7000 times overall). In addition, he has over 4000 on ResearchGate.

The review article, “Stability of Protein Pharmaceuticals: An Update”, published by Legacy scientists in 2010, has now been cited almost 300 times.


Ryan Holcomb, Brian Murphy, Robert Payne, and Ryan Manning (Great Lakes BioDesign) all completed “Light Scattering University” in 2014, which is a rigorous 3-day training program held at Wyatt Instruments (Goleta, CA).  Wyatt Instruments is part of the Legacy BioDesign strategic network.

Ryan Manning heads Great Lakes Bio Design (Charlotte, MI), with a focus on AF4 method development and analysis of biopharmaceuticals. Great Lakes BioDesign (GLB) began operation in January of 2014. As part of our distributed analytical network, GLB has already contributed to more than seven projects in its first year of operation.

Our partnership with West Coast BioDesign (WCB) has focused on improving the methodology for characterization and quantitation of subvisible particles (SVPs). Recently, Glenn Wilson from WCB and Mark Manning published a summary of their observations about flow imaging techniques and what needs to be done to establish the best practices for this important methodology. The article is called “Flow Imaging: Moving Towards Best Practices for Subvisible Particle Quantitation in Protein Products”, Glenn A. Wilson and Mark Cornell Manning, J. Pharm. Sci. 2013, 102: 1133-1134.


Legacy has an important collaboration with Dr. Wasfi Al-Azzam and his group at GSK on the use of analytical methods to determine and compare higher order structure in proteins. Recently, two more papers were published, with Brian Murphy and Mark Manning from Legacy as co-authors.

“Use of the Amide II Infrared Band of Proteins for Secondary Structure Determination and Comparability of Higher Order Structure”, Brian M. Murphy, Jennifer D’Antonio, Mark Cornell Manning, and Wasfi A. Al-Azzam, Curr. Pharm. Biotechnol. 2014, 15(9): 880-889.

“Comparability of Higher Order Structure in Proteins: Chemometric Analysis of Second Derivative Amide I Fourier Transform Infrared (FTIR) Spectra”, Gregory Stockdale, Brian M. Murphy, Jennifer D’Antonio, Mark Cornell Manning, and Wasfi A. Al-Azzam, J. Pharm. Sci. 2015, 104(1): 25-33.

Mark Manning will be presenting at HOS 2016, a conference sponsored by CASSS on Higher Order Structure (April 11-13, 2016). The title of his talk will be “Quantitative Assessment of Higher Order Structure: Developing Novel Mathematical Tools for Comparability Testing”